| Literature DB >> 32763221 |
Jillian Pintye1, Dvora L Joseph Davey2, Anjuli D Wagner3, Grace John-Stewart4, Rachel Baggaley5, Linda-Gail Bekker6, Connie Celum7, Benjamin H Chi8, Thomas J Coates9, Allison K Groves10, Jessica E Haberer11, Renee Heffron12, John Kinuthia13, Lynn T Matthews14, James A McIntyre15, Dhayendre Moodley16, Lynne M Mofenson17, Nelly Mugo18, Andrew Mujugira19, Landon Myer20, Steven Shoptaw9, Lynda Stranix-Chibanda21, Jared M Baeten7.
Abstract
Pregnancy is a high-risk period for HIV acquisition in African women, and pregnant women who become acutely infected with HIV account for up to a third of vertical HIV transmission cases in African settings. To protect women and eliminate vertical transmission, WHO recommends offering oral pre-exposure prophylaxis (PrEP) based on tenofovir to HIV-negative pregnant and post-partum women with a substantial risk of HIV acquisition. PrEP implementation for pregnant and post-partum women lags behind implementation for other high-risk populations. Unique considerations for PrEP implementation arise during pregnancy and post partum, including the integration of provider training with clinical delivery and monitoring of PrEP exposure and outcomes within existing maternal health systems, yet scarce implementation data are available to generate evidence in this context.Entities:
Mesh：
Substances：
Year: 2020 PMID： 32763221 PMCID： PMC7587402 DOI： 10.1016/S2352-3018(20)30102-8
Source DB: PubMed Journal: Lancet HIV ISSN： 2352-3018 Impact factor: 12.767